Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
JNCI Cancer Spectr 2022 Jul 01;6(4)pkac043, ND James, FC Ingleby, NW Clarke, CL Amos, G Attard, CD Brawley, S Chowdhury, W Cross, DP Dearnaley, DC Gilbert, S Gillessen, RJ Jones, RE Langley, A Macnair, ZI Malik, MD Mason, DJ Matheson, R Millman, CC Parker, HL Rush, JM Russell, C Au, AWS Ritchie, RP Mestre, I Ahmed, AJ Birtle, SJ Brock, P Das, VA Ford, EK Gray, RJ Hughes, CB Manetta, DB McLaren, AD Nikapota, JM O'Sullivan, C Perna, C Peedell, AS Protheroe, S Sundar, JS Tanguay, SP Tolan, J Wagstaff, JB Wallace, JP Wylie, A Zarkar, MKB Parmar, MR SydesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.